Japan Vaccine Co. Ltd.

Japan has one of the largest single-country pharma markets in the world, a handful of major R&D-based companies with multiple innovative drugs sold around the globe, and a record of innovation that st

In line with an increased focus on its oncology operations, which are now moving towards commercialization, Daiichi Sankyo Co. Ltd. is realigning its R&D activities in Japan and taking other steps t

Daiichi Sankyo Co. Ltd. has unveiled further reorganization of its vaccines activities in Japan, as it appears to be de-emphasizing the field amid a strategic pivot towards oncology and generic chall

Officials at the European Commission and Japan’s Ministry of Health, Labour and Welfare (MHLW) have approved Shingrix , the GlaxoSmithKline PLC non-live, recombinant subunit vaccine, for the preven